\
&
Contact us
\
&
Contact us
This was 2 years ago
Locationvirtual
ProgrammesA series of virtual information days is organised by the EIC Programme Managers on the European Innovation Council Pathfinder, Transition and Accelerator Challenges 2023 calls.
The sessions will take place in January, February and March. The full schedule of info days is available here
Only for the two sessions on 26 January prior registration is required. All sessions will be recorded and the recordings will be made available after the info days in the EIC event announcements.
In several sessions applicants searching for project partners have the option to present themselves in a very short presentation. In the majority of those sessions, the applicants interested to present are requested to contact the organisers before the info day.
Each info day of the EIC Challenges info days series can be found in our event calendar or on the EIC programme page on our website (bottom of the page).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
